Key Takeaways:
Powered by lumidawealth.com
- 2025 revenue forecast: $61-64B
- Adjusted EPS target: $2.80-3.00
- $1B impact from Medicare changes
- Stock up 3% in premarket
- Quarterly dividend increased
What Happened?
Pfizer announced its 2025 financial outlook, maintaining steady guidance despite headwinds from Medicare Part D benefit redesign. The forecast comes as the company faces pressure from activist investor Starboard Value and works to recover from a post-Covid slump.
Why It Matters?
The development signals:
- Post-pandemic transition strategy
- Shareholder confidence measures
- Healthcare policy impacts
- Market positioning
- Corporate resilience
What’s Next?
Watch for:
- 2024 full-year results (February)
- Covid product performance
- Activist investor response
- R&D investment outcomes
- Medicare policy impacts